Successful partnerships are an integral part of our business strategy. We share with our partners a strong commitment to discovering, developing and commercializing innovative molecular targeted therapies addressing major unmet medical needs in oncology and diabetes & obesity. We understand that we can more rapidly advance scientific innovations to shape medicine and thus change lives of patients through partnerships with academic and industrial collaborators beyond our organization.

OSI has unique balance of the biotech mindset and big pharma capabilities. We understand biotech culture and are entrepreneurial with swift actions and great flexibility. We have a long history of successful partnerships with industry and academia.

We have gained a wealth of experience from current and past partnerships and collaborations with proven success. Tarceva (erlotinib) was discovered from the OSI/Pfizer collaboration and about 10 other compounds from collaborations are currently in clinical development. We are currently partnering with world-class organizations, including Genentech, Roche, and Eli Lilly.

OSI is open to collaboration opportunities whenever there is a strong scientific merit with a strategic fit.

To contact OSI regarding a potential collaboration, please use the Contact Information page.